efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
Published 2 years ago • 767 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
1:19
treatment recommendations for patients with cll with del(17p) and tp53 aberrations
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:01
real-world analysis of the impact of del(17p) on ibrutinib efficacy in cll
-
2:21
outcomes of tp53-disrupted cll patients treated with frontline ibrutinib
-
12:26
treating ultra high risk myeloma patients in a unique uk study | martin kaiser, md | ash 2021
-
3:08
recent updates on tp53 mutation in cll
-
5:59
what is hrmm (high-risk multiple myeloma)?
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:12
the impact of genetic abnormalities on treatment decisions in cll
-
1:37
causes & management of ibrutinib discontinuation in cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
1:56
ibrutinib treatment and its associated risk factors
-
2:25
key ebmt guideline updates for the treatment and prophylaxis of gvhd
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
1:38
the importance of tp53 in cll
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
2:14
ibrutinib's role in cll treatment and future outlooks
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis